Edition:
United Kingdom

Lipocine Inc (LPCN.OQ)

LPCN.OQ on NASDAQ Stock Exchange Capital Market

1.55USD
25 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.55
Open
$1.55
Day's High
$1.56
Day's Low
$1.50
Volume
10,095
Avg. Vol
80,391
52-wk High
$5.32
52-wk Low
$1.16

Select another date:

Mon, Mar 12 2018

BRIEF-Lipocine Says ‍As Of December 31, 2017 Co Had Cash, Cash Equivalents And Marketable Securities Of $21.5 Mln​

* LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017

BRIEF-Lipocine Announces Settlement Of Securities Class Action Lawsuit

* LIPOCINE ANNOUNCES SETTLEMENT OF SECURITIES CLASS ACTION LAWSUIT

BRIEF-Lipocine Announces $10 Mln Loan And Security Agreement With Silicon Valley Bank

* LIPOCINE ANNOUNCES $10 MILLION LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK Source text for Eikon: Further company coverage:

BRIEF-Lipocine Says FDA's BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of Tlando

* LIPOCINE - FDA'S BRUDAC VOTED 6 IN FAVOR & 13 AGAINST BENEFIT/RISK PROFILE OF CO'S ORAL TESTOSTERONE PRODUCT CANDIDATE FOR TRT IN ADULT MALES, TLANDO

BRIEF-Lipocine Says On Jan 5, Co, Unit, Silicon Valley Bank Entered Into Loan, Security Agreement

* LIPOCINE INC SAYS ON JAN 5, CO, UNIT, SILICON VALLEY BANK ("SVB") ENTERED INTO A LOAN AND SECURITY AGREEMENT -SEC FILING

BRIEF-Lipocine says ‍FDA assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando​

* U.S. FDA extends review for Tlando™; advisory committee meeting date of January 10, 2018 remains unchanged

BRIEF-Lipocine Inc Q3 loss per share $0.22

* Lipocine announces financial and operational results for the third quarter and nine months ended September 30, 2017

Select another date: